{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:54:50Z","timestamp":1787007290472,"version":"build-2736575974"},"reference-count":63,"publisher":"Informa UK Limited","issue":"10","funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2016,10,2]]},"DOI":"10.1080\/14712598.2016.1221920","type":"journal-article","created":{"date-parts":[[2016,8,12]],"date-time":"2016-08-12T18:37:13Z","timestamp":1471027033000},"page":"1291-1301","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma"],"prefix":"10.1080","volume":"16","author":[{"given":"Sagar","family":"Lonial","sequence":"first","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Kaufman","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Reece","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[{"name":"Haematology Department, Complejo Asistencial Universitario de Salamanca-IBSAL, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Laubach","sequence":"additional","affiliation":[{"name":"Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[{"name":"Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,8,17]]},"reference":[{"key":"CIT0001","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Multiple Myeloma. Version 3; 2016 [cited 2016 Feb 2]. Available from: http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp."},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21254"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8983"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt297"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.48.7934"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"CIT0007","first-page":"210","volume":"23","author":"Kumar L","year":"2010","journal-title":"Natl Med J India"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-395749"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2014.12.026"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.196"},{"key":"CIT0011","volume-title":"Ninlaro (ixazomib) Prescribing Information","year":"2015"},{"key":"CIT0012","volume-title":"Farydak (panobinostat) prescribing information","year":"2016"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra072739"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds256"},{"key":"CIT0015","first-page":"767","volume":"13","author":"Luptakova K","year":"2015","journal-title":"Clin Adv Hematol Oncol"},{"key":"CIT0016","volume-title":"Darzalex (daratumumab) Prescribing information","year":"2015"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01120-4"},{"key":"CIT0018","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1182\/blood.V126.23.3037.3037","volume":"126","author":"Krejcik J","year":"2015","journal-title":"Blood"},{"key":"CIT0019","doi-asserted-by":"crossref","first-page":"8574","DOI":"10.1200\/jco.2015.33.15_suppl.8574","volume":"33","author":"Raab M","year":"2015","journal-title":"J Clin Oncol"},{"key":"CIT0020","volume-title":"Empliciti (elotuzumab) prescribing Information","year":"2015"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4246"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1505654"},{"key":"CIT0023","unstructured":"ClinicalTrials.gov. Phase III Study of lenalidomide and dexamethasone with and without elotuzumab to treat newly diagnosed, previously untreated multiple myeloma. 2015 [cited 2016 Apr 3]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01335399?term=01335399&rank=1."},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-107292"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-560862"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1493-8"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01107-14"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2013.847919"},{"key":"CIT0029","volume":"101","author":"Bezman N","year":"2016","journal-title":"Haematologica"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-360552"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.7069"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.2649"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.12.007"},{"key":"CIT0034","volume":"22","author":"Berenson J","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"CIT0035","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00197-0"},{"key":"CIT0036","volume-title":"The 20th Congress of the European Hematology Association (EHA)","author":"Jakubowiak A","year":"2015"},{"key":"CIT0037","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1182\/blood.V126.23.510.510","volume":"126","author":"Palumbo A","year":"2015","journal-title":"Blood"},{"key":"CIT0038","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood.V126.23.2093.2093","volume":"126","author":"Dimopoulos MA","year":"2015","journal-title":"Blood"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25139"},{"key":"CIT0040","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-010-1080-4"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694604"},{"key":"CIT0042","volume":"101","author":"Poulart V","year":"2016","journal-title":"Haematologica"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08644.x"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2010.152116"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2015-0888"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2015.07.561"},{"key":"CIT0047","volume-title":"57th Annual Meeting & Exposition of American Society of Hematology (ASH)","author":"Dimopoulos MA","year":"2015"},{"key":"CIT0048","unstructured":"ClinicalTrials.gov. S1211, bortezomib, dexamethasone, and lenalidomide with and without elotuzumab in treating patients with newly diagnosed high-risk multiple myeloma. 2015 [cited 2016 Mar 4]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01668719?term=NCT01668719&rank=1."},{"key":"CIT0049","unstructured":"ClinicalTrials.gov. A Phase I open label study of the safety and tolerability of elotuzumab (BMS-901608) administered in combination with either lirilumab (BMS-986015) or urelumab (BMS-663513) in subject with multiple myeloma (Study 028) (NCT02252263). 2015 [cited 2016 Mar 4]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02252263?term=02252263&rank=1."},{"key":"CIT0050","unstructured":"ClinicalTrials.gov. Japanese study of (BMS-901608) (elotuzumab) in combination with lenalidomide and low dose dexamethasone. 2015 [cited 2016 Mar 4]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01241292."},{"key":"CIT0051","unstructured":"ClinicalTrials.gov. Elotuzumab in autologous stem cell transplantation (ASCT) and lenalidomide maintenance for multiple myeloma. 2016 [cited 2016 Mar 4]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02655458?term=NCT02655458&rank=1."},{"key":"CIT0052","unstructured":"ClinicalTrials.gov. Study of elotuzumab with lenalidomide as maintenance after autologous stem cell transplant (ASCT). 2015 [cited 2016 Mar 4]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02420860?term=NCT02420860&rank=1."},{"key":"CIT0053","unstructured":"ClinicalTrials.gov. Study of bortezomib, lenalidomide, dexamethasone & elotuzumab in newly diagnosed MM. 2015 [cited 2016] Mar 4]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02375555?term=NCT02375555&rank=1"},{"key":"CIT0054","unstructured":"ClinicalTrials.gov. Safety study of elotuzumab in combination with thalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma. 2015 [cited 2016 Mar 4]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01632150?term=NCT01632150&rank=1."},{"key":"CIT0055","unstructured":"ClinicalTrials.gov. Trial of elotuzumab with or without pomalidomide and low-dose dexamethasone to treat refractory and relapsed and refractory multiple myeloma. 2015 [cited 2016 Feb 2]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02654132?term=NCT02654132&rank=1."},{"key":"CIT0056","unstructured":"ClinicalTrials.gov. A study of Elotuzumab in combination with pomalidomide and low dose dexamethasone (EPd) in patients with multiple myeloma relapsed or refractory to prior treatment with lenalidomide (Study 142) (NCT02612779). 2015 [cited 2016 Mar 4]. Available from: https:\/\/www.clinicaltrial.gov\/ct2\/show\/NCT02612779?term=02612779&rank=1"},{"key":"CIT0057","unstructured":"ClinicalTrials.gov. Biomarker study of elotuzumab in high risk smoldering myeloma. 2015 [cited 2016] Mar 4]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01441973?term=NCT01441973&rank=1."},{"key":"CIT0058","unstructured":"ClinicalTrials.gov. Trial of combination of elotuzumab and lenalidomide \u00b1 dexamethasone in high-risk smoldering multiple myeloma. 2015 [cited 2016. Mar 4]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02279394?term=NCT02279394&rank=1."},{"key":"CIT0059","unstructured":"ClinicalTrials.gov. PH III study of lenalidomide and dexamethasone with and without elotuzumab to treat previously untreated multiple myeloma (ELO 1 Substudy). 2015 [cited 2016 Mar 4]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01891643?term=NCT01891643&rank=1."},{"key":"CIT0060","unstructured":"ClinicalTrials.gov. A Phase III trial on the effect of elotuzumab in VRD induction\/consolidation and lenalidomide maintenance in patients with newly diagnosed multiple myeloma (GMMG-HD6). 2015 [cited 2016 Mar 4]. Availablefrom: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02495922?term=NCT02495922&rank=1."},{"key":"CIT0061","unstructured":"ClinicalTrials.gov. Study of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Multiple Myeloma (CheckMate 602) (NCT02726581). 2016 [cited 2016 Apr 6]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02726581."},{"key":"CIT0062","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.62"},{"key":"CIT0063","unstructured":"EMA. Elotuzumab: Summary of product characteristics. 2016 [cited 2016 May 26]. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/003967\/WC500206673.pdf."}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2016.1221920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,16]],"date-time":"2020-08-16T16:45:26Z","timestamp":1597596326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2016.1221920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,17]]},"references-count":63,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10,2]]}},"alternative-id":["10.1080\/14712598.2016.1221920"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2016.1221920","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"value":"1471-2598","type":"print"},{"value":"1744-7682","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-08-04","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-08-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}